Reeling from an unexpected move by regulators, Catalyst Pharmaceuticals (CPRX) is threatening to hit back.

Until recently, the drug maker had been riding high. Last November, the Food and Drug Administration approved its medicine for treating adults with a rare neuromuscular disorder called LEMS, which meant Catalyst has seven years of marketing exclusivity. And despite controversy over its $375,000 price tag, the company appeared to have silenced some critics with assistance programs that kept patient out-of-pocket costs low. Meanwhile, its soaring stock price pleased investors.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Hmmm, the potential for ‘off-label use.’ Is there anyone who actually believes that Catalyst wasn’t counting on the potential for that with their drug in the first place?
    [And as Catalyst ponders/ threatens, one might observe that their projection of a 10x larger market size was a questionable bit of bait [ not fraud, of course] for drawing investors? One might … ]

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy